Company Profile
Bio-Path Holdings Stock Price, News & Analysis
- Ticker:
- BPTH
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.05 USD (+19.74%)
Close
Last updated: August 6, 2026
—
Market cap
Why the stock is moving
As of Aug 6, 2026, BPTH closed up 19.7% at $0.0455. No new same-company headline was identified in the current news window.
Company overview
Business overview
Bio-Path Holdings is a biotechnology company focused on RNAi and nucleic-acid-based approaches to cancer. Its story has long centered on specialized oncology science and the challenge of turning it into a commercial asset.
Geographic Base and Sector Classification
Bio-Path is headquartered in the United States and listed on NASDAQ. It sits in small-cap oncology biotechnology.
Business Model Characteristics
The company depends on clinical progress, preclinical validation, and capital discipline to keep its programs moving. Investors usually watch readouts, safety, and the ability to sustain runway.
Position Within the Biotechnology Landscape
Bio-Path occupies a niche oncology platform position within biotech. It is highly sensitive to whether its nucleic-acid science can translate into differentiated cancer activity.
Future catalysts
Bio-Path’s catalysts are liposomal oncology programs and any clinical update that keeps the platform credible. The stock remains highly sensitive to whether the next data point improves the development path.
Recent news
- 01
Bio-Path Holdings to Present at Life Sciences Virtual Investor Forum
Source: Bio-Path Holdings
- 02
Bio-Path Holdings Provides Clinical and Operational Update
Source: Bio-Path Holdings
- 03
Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025
Source: Bio-Path Holdings
- 04
- 05
Bio-Path Holdings Reports Full Year 2024 Financial Results
Source: Bio-Path Holdings
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Bio-Path Holdings (BPTH)?
Bio-Path Holdings (BPTH) most recently closed at 0.05 USD, a +19.74% move versus the previous session.
What does Bio-Path Holdings do?
Bio-Path Holdings is a biotechnology company focused on RNAi and nucleic-acid-based approaches to cancer. Its story has long centered on specialized oncology science and the challenge of turning it into a commercial asset.
On which exchange is BPTH stock listed?
Bio-Path Holdings (BPTH) is associated with NASDAQ, United States, Biopharma.
What is Bio-Path?
Bio-Path’s catalysts are liposomal oncology programs and any clinical update that keeps the platform credible.
Which conditions is Bio-Path Holdings targeting with Bio-Path?
Bio-Path Holdings is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Bio-Path Holdings describe recent progress with Bio-Path?
Bio-Path’s catalysts are liposomal oncology programs and any clinical update that keeps the platform credible.
What is Holdings?
Bio-Path Holdings is a biotechnology company focused on RNAi and nucleic-acid-based approaches to cancer.
What should investors watch for with Holdings?
Bio-Path’s catalysts are liposomal oncology programs and any clinical update that keeps the platform credible. The stock remains highly sensitive to whether the next data point improves the development path.